Study to Assess Therapeutic Efficacy and Information Tracking Benefits of Neurostimulation Device

A press release from the manufacturer, NeuroMetrix, Inc., has announced a new clinical trial of its Quell® Wearable Pain relief TechnologyTM that will be conducted at the Brigham and Women’s Hospital Pain Management Center in Boston. The Quell wearable device uses neurostimulation technology to provide analgesic therapy to patients with chronic low back pain. The device additionally tracks utilization and health metrics such as sleep and activity levels. An upgraded version of the Quell system was released in March of this year. Studies conducted to date have indicated therapeutic efficacy as measured by improvements in Patient Global Impression of Change (SGIC) scores, and reduced reliance on analgesic medications among users.

The new clinical trial will comprise a 3-month single site, controlled randomized study of 60 adult patients with chronic low back pain. Subjects will be randomized to “treatment as usual” or treatment with the Quell device. Both cohorts will receive Quantitative Sensory Testing at baseline, and will document and track their pain levels using a smartphone app developed at the B&W Pain Management Center. Shai Gozani, MD, PhD, President and CEO of NeuroMetrix, commented, “This study will analyze the potential for Quell to reduce pain and improve quality of life in people suffering from chronic low back pain.”

Read the news release here.

 

Share:

Related Content